Portfolio company
Alentis Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
7 investors
Sectors
About
Alentis Therapeutics develops anti-Claudin-1 antibodies and antibody-drug conjugates to treat patients with organ fibrosis and various solid tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Alevin Therapeutics
This biotechnology company develops small molecule integrin inhibitors to treat patients with life-threatening fibrotic diseases, including lung, liver and kidney conditions.
Alentar
This company develops therapeutic agents to reverse goblet cell hyperplasia for patients with cystic fibrosis and other pulmonary conditions.
Northern Biologics
This company develops antibody-based therapeutics targeting the tumour microenvironment to treat patients with cancer and fibrosis.
Valink Therapeutics
Valink Therapeutics develops next-generation bispecific antibody-drug conjugates to treat solid tumours for cancer patients.
Aqualung
Aqualung Therapeutics develops immunotherapeutic monoclonal antibodies for patients suffering from inflammatory lung injuries and life-threatening fibrosis.
Araris Biotech
This company develops antibody-drug conjugate linker technology and targeted cancer therapies for pharmaceutical partners and patients.
AgomAb Therapeutics
This biopharmaceutical company develops therapies to treat fibrotic and inflammatory diseases for patients with conditions such as Crohn's disease and pulmonary fibrosis.
Calluna Pharma
This clinical-stage company develops monoclonal antibodies to treat inflammatory and fibrotic diseases for patients with conditions like idiopathic pulmonary fibrosis and chronic kidney disease.